Bluebird Bio (NASDAQ: BLUE) reported Q2 EPS of ($0.06), $0.39 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $6.3 million versus the consensus estimate of $6.15 million.

For earnings history and earnings-related data on Bluebird Bio (BLUE) click here.